COMP <GO>
BELFB vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Bel Fuse Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: BELFB 5
— TMO 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BELFB
LAST: $235.73 (+3.50%) • MKT CAP: $3.40B
balance-sheet
6.95
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BELFB VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BELFB | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.50% | 9.30% | +6.20 | BELFB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.2x | 30.4x | -1.20 | BELFB | /valuation <GO> |
| Free Cash Flow Yield | 2.02% | 2.40% | -0.38 | TMO | /fcf-yield <GO> |
| Operating Margin | 16.40% | 17.40% | -1.00 | TMO | /operating-margins <GO> |
| Net Profit Margin | 11.00% | 15.10% | -4.10 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 26.30% | 3.90% | +22.40 | BELFB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.10% | 0.24% | -0.14 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 6.95 | 4.50 | +2.45 | BELFB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | BELFB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 62.9 | -9.80 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 38.6x | 36.3x | +2.30 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.40B | $262.22B | -$258.81B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BELFB REV | TMO REV | BELFB GROSS % | TMO GROSS % | BELFB FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $675.5M | $44.56B | 39.1% | — | $68.6M | $6.29B |
| FY 2024 | $534.8M | $42.88B | 37.8% | — | $60.0M | $7.27B |
| FY 2023 | $639.8M | $42.86B | — | — | $79.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BELFB // BETA 0.89
TMO // BETA 0.94